PROTALIX BIOTHERAP.DL-01
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also dev… Read more
PROTALIX BIOTHERAP.DL-01 (PBDA) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, PROTALIX BIOTHERAP.DL-01 (PBDA) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
PROTALIX BIOTHERAP.DL-01 - Net Assets Trend (None–None)
This chart illustrates how PROTALIX BIOTHERAP.DL-01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PROTALIX BIOTHERAP.DL-01 (None–None)
The table below shows the annual net assets of PROTALIX BIOTHERAP.DL-01 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to PROTALIX BIOTHERAP.DL-01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
PROTALIX BIOTHERAP.DL-01 Competitors by Market Cap
The table below lists competitors of PROTALIX BIOTHERAP.DL-01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hes Technology Group
SHE:002963
|
$143.68 Million |
|
PowerCell Sweden AB (publ)
PINK:PCELF
|
$143.74 Million |
|
Linc AB
ST:LINC
|
$143.77 Million |
|
Shanghai National Center of Testing and Inspection for Electric Cable and Wire Co. Ltd.
SHE:301289
|
$143.81 Million |
|
Diamyd Medical AB (publ)
ST:DMYD-B
|
$143.63 Million |
|
Elicio Therapeutics Inc.
NASDAQ:ELTX
|
$143.62 Million |
|
Benchmark Metals Inc
V:CEI
|
$143.60 Million |
|
CAMP4 THERAPEUTICS CORPORATION
NASDAQ:CAMP
|
$143.59 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PROTALIX BIOTHERAP.DL-01's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares PROTALIX BIOTHERAP.DL-01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently PROTALIX BIOTHERAP.DL-01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares PROTALIX BIOTHERAP.DL-01's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PROTALIX BIOTHERAP.DL-01 (PBDA) | €- | N/A | N/A | $143.64 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |